Compugen (CGEN)
(Delayed Data from NSDQ)
$1.68 USD
-0.04 (-2.33%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $1.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.68 USD
-0.04 (-2.33%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $1.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Zacks News
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
by Zacks Equity Research
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
by Zacks Equity Research
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
by Zacks Equity Research
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
by Zacks Equity Research
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
by Zacks Equity Research
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up
by Zacks Equity Research
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
by Zacks Equity Research
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
by Zacks Equity Research
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
by Zacks Equity Research
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
by Zacks Equity Research
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
by Zacks Equity Research
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
by Zacks Equity Research
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
by Zacks Equity Research
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Compugen (CGEN) delivered earnings and revenue surprises of 20% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
BOX Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
BOX's fourth-quarter fiscal 2024 results are likely to reflect gains from the growing adoption of content cloud solutions.
Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?
by Zacks Equity Research
Petrobras (PBR) beat the Zacks Consensus Estimate in two of the last four quarters and missed in the other two, which resulted in an earnings surprise of 3.8%, on average.
Is a Surprise Coming for Compugen (CGEN) This Earnings Season?
by Zacks Equity Research
Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Baidu (BIDU) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Baidu's (BIDU) fourth-quarter results are likely to reflect the benefits of its AI business and growing autonomous driving efforts amid uncertainties in China.
Vipshop (VIPS) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Vipshop's (VIPS) fourth-quarter results are expected to reflect strength in its merchandising strategy and discount retail business amid macroeconomic challenges in China.
ACM Research (ACMR) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
ACM Research's (ACMR) fourth-quarter 2023 results are expected to reflect gains from semiconductor, ECP and advanced packaging businesses.
What to Look for in Crescent Point's (CPG) Q4 Earnings?
by Zacks Equity Research
Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.